Tikva Allocell Secures $8 Million to Transform Solid Tumor Therapy
July 30, 2026, 3:35 pm
Location: United States
Employees: 5001-10000
Founded date: 1900
Total raised: $12.5M
Tikva Allocell secured substantial funding. The biotechnology firm, based in Singapore, announced an $8 million Series A financing round. Kantharos Capital led this crucial investment. This capital injection significantly accelerates a pioneering cell therapy. The funds are earmarked for vital development activities. They support an Investigational New Drug (IND) application. Tikva targets a late 2026 IND submission for TAVST01. This represents a major regulatory milestone.
TAVST01 is Tikva’s leading therapeutic candidate. It is designed to target B7-H3-positive solid tumors. Such tumors include difficult-to-treat cancers. Lung, breast, and prostate cancers fall into this category. Pancreatic and pediatric malignancies also pose significant challenges. These cancers often resist current treatments.
Solid tumors present unique hurdles for cell therapies. Donor-derived cell therapies face immediate obstacles. Patient immune systems frequently recognize and reject these cells. This rapid clearance prevents therapeutic action. Furthermore, donor cells often fail to persist long enough. They cannot establish a durable presence in the body. The dense tumor microenvironment also creates a barrier. It limits cell infiltration and function. This has historically stalled cell therapy progress in solid oncology.
Tikva Allocell’s innovative approach confronts these limitations. Its TAVST01 therapy reimagines allogeneic cell therapy. The platform harnesses Epstein-Barr virus (EBV)-specific T cells. These immune cells are naturally sustained by the human body. Nearly everyone carries dormant EBV. This provides a robust and persistent source for therapeutic cells. Tikva engineers these EBV-specific T cells for enhanced efficacy.
The therapy's foundation is the ALLO SerpinB9 EBVST platform. This advanced, allogeneic, virus-specific T-cell technology originated from Baylor College of Medicine. Tikva holds an exclusive license for its use. The platform integrates a B7-H3-targeting receptor. This receptor precisely guides the T cells. They identify and bind to cancer cells expressing B7-H3. This protein is widely expressed across many aggressive solid tumors.
A key differentiator is the optimized SerpinB9 component. SerpinB9 acts as a natural inhibitor. It specifically blocks granzyme B. Granzyme B is an enzyme deployed by a patient's immune cells. Its function is to destroy foreign, donor cells. Tikva’s SerpinB9 “armor” protects TAVST01 cells. This engineering allows the therapeutic cells to resist host immune rejection. They survive and function longer within the patient. This extended persistence is paramount for effective solid tumor treatment.
This sophisticated approach offers multi-pronged action. TAVST01 directly engages and eliminates tumor cells. It also actively modulates the immunosuppressive microenvironment. This hostile environment typically shields cancer from immune attacks. By transforming this critical barrier, TAVST01 enhances its therapeutic impact. The therapy seeks to offer greater potency and durability. It represents a major leap toward scalable and accessible cancer treatment.
The platform is meticulously designed for safety. It aims to significantly reduce the risk of graft-versus-host disease (GvHD). GvHD is a severe, life-threatening complication. It commonly affects recipients of allogeneic transplants. Tikva achieves this improved safety profile with minimal gene editing. This careful design underscores a commitment to patient well-being. It promises a more tolerable and safer therapeutic option.
The scientific bedrock of Tikva Allocell is strong. Extensive research from Baylor College of Medicine forms its core. Esteemed pioneers in cell therapy laid this groundwork. Dr. Malcolm Brenner, Dr. Cliona Rooney, and Dr. Helen Heslop are foundational figures. They are Tikva's scientific co-founders, alongside CEO Dr. Ivan Horak. Their collective expertise propels the company's innovative trajectory.
The newly secured Series A funding empowers Tikva for accelerated progress. The company will now finalize IND-enabling studies. These preclinical assessments are crucial. They generate comprehensive data on safety and potential efficacy. This data is mandatory for regulatory submission. The targeted year-end 2026 IND filing represents a significant step. It brings TAVST01 closer to clinical evaluation.
Following successful regulatory clearance from health authorities, clinical trials will commence. Tikva plans to initiate a Phase 1 clinical trial. Patients diagnosed with advanced B7-H3-positive cancer will be recruited. Trial sites are planned for both Singapore and the United States. This strategic global presence facilitates broader patient access. It also accelerates the collection of diverse clinical data.
Kantharos Capital conveyed strong confidence in Tikva. Their investment reflects a firm conviction in the company’s scientific foundation. It also validates the strength and vision of its leadership team. Tikva directly confronts persistent, fundamental challenges. These challenges have long constrained allogeneic cell therapies. The ALLO SerpinB9 EBVST platform shows immense promise. It holds the potential to vastly extend the reach of cell therapy. This offers new hope for solid tumor patients, who often face dire prognoses and limited treatment options.
This funding round marks a pivotal moment for Tikva Allocell. It underscores growing investor belief in next-generation cell therapies. The global biotechnology sector closely monitors such breakthroughs. Tikva Allocell is poised to potentially transform oncology. The company pushes the boundaries of conventional cancer treatment. Its unique EBV-specific T-cell approach illuminates a new path forward. This path promises durable, life-changing responses for solid tumor patients. It signifies a profound advancement in precision medicine. The future landscape of solid tumor treatment may be profoundly shaped by these engineered cells. Tikva is actively preparing to lead this transformative charge.
TAVST01 is Tikva’s leading therapeutic candidate. It is designed to target B7-H3-positive solid tumors. Such tumors include difficult-to-treat cancers. Lung, breast, and prostate cancers fall into this category. Pancreatic and pediatric malignancies also pose significant challenges. These cancers often resist current treatments.
Solid tumors present unique hurdles for cell therapies. Donor-derived cell therapies face immediate obstacles. Patient immune systems frequently recognize and reject these cells. This rapid clearance prevents therapeutic action. Furthermore, donor cells often fail to persist long enough. They cannot establish a durable presence in the body. The dense tumor microenvironment also creates a barrier. It limits cell infiltration and function. This has historically stalled cell therapy progress in solid oncology.
Tikva Allocell’s innovative approach confronts these limitations. Its TAVST01 therapy reimagines allogeneic cell therapy. The platform harnesses Epstein-Barr virus (EBV)-specific T cells. These immune cells are naturally sustained by the human body. Nearly everyone carries dormant EBV. This provides a robust and persistent source for therapeutic cells. Tikva engineers these EBV-specific T cells for enhanced efficacy.
The therapy's foundation is the ALLO SerpinB9 EBVST platform. This advanced, allogeneic, virus-specific T-cell technology originated from Baylor College of Medicine. Tikva holds an exclusive license for its use. The platform integrates a B7-H3-targeting receptor. This receptor precisely guides the T cells. They identify and bind to cancer cells expressing B7-H3. This protein is widely expressed across many aggressive solid tumors.
A key differentiator is the optimized SerpinB9 component. SerpinB9 acts as a natural inhibitor. It specifically blocks granzyme B. Granzyme B is an enzyme deployed by a patient's immune cells. Its function is to destroy foreign, donor cells. Tikva’s SerpinB9 “armor” protects TAVST01 cells. This engineering allows the therapeutic cells to resist host immune rejection. They survive and function longer within the patient. This extended persistence is paramount for effective solid tumor treatment.
This sophisticated approach offers multi-pronged action. TAVST01 directly engages and eliminates tumor cells. It also actively modulates the immunosuppressive microenvironment. This hostile environment typically shields cancer from immune attacks. By transforming this critical barrier, TAVST01 enhances its therapeutic impact. The therapy seeks to offer greater potency and durability. It represents a major leap toward scalable and accessible cancer treatment.
The platform is meticulously designed for safety. It aims to significantly reduce the risk of graft-versus-host disease (GvHD). GvHD is a severe, life-threatening complication. It commonly affects recipients of allogeneic transplants. Tikva achieves this improved safety profile with minimal gene editing. This careful design underscores a commitment to patient well-being. It promises a more tolerable and safer therapeutic option.
The scientific bedrock of Tikva Allocell is strong. Extensive research from Baylor College of Medicine forms its core. Esteemed pioneers in cell therapy laid this groundwork. Dr. Malcolm Brenner, Dr. Cliona Rooney, and Dr. Helen Heslop are foundational figures. They are Tikva's scientific co-founders, alongside CEO Dr. Ivan Horak. Their collective expertise propels the company's innovative trajectory.
The newly secured Series A funding empowers Tikva for accelerated progress. The company will now finalize IND-enabling studies. These preclinical assessments are crucial. They generate comprehensive data on safety and potential efficacy. This data is mandatory for regulatory submission. The targeted year-end 2026 IND filing represents a significant step. It brings TAVST01 closer to clinical evaluation.
Following successful regulatory clearance from health authorities, clinical trials will commence. Tikva plans to initiate a Phase 1 clinical trial. Patients diagnosed with advanced B7-H3-positive cancer will be recruited. Trial sites are planned for both Singapore and the United States. This strategic global presence facilitates broader patient access. It also accelerates the collection of diverse clinical data.
Kantharos Capital conveyed strong confidence in Tikva. Their investment reflects a firm conviction in the company’s scientific foundation. It also validates the strength and vision of its leadership team. Tikva directly confronts persistent, fundamental challenges. These challenges have long constrained allogeneic cell therapies. The ALLO SerpinB9 EBVST platform shows immense promise. It holds the potential to vastly extend the reach of cell therapy. This offers new hope for solid tumor patients, who often face dire prognoses and limited treatment options.
This funding round marks a pivotal moment for Tikva Allocell. It underscores growing investor belief in next-generation cell therapies. The global biotechnology sector closely monitors such breakthroughs. Tikva Allocell is poised to potentially transform oncology. The company pushes the boundaries of conventional cancer treatment. Its unique EBV-specific T-cell approach illuminates a new path forward. This path promises durable, life-changing responses for solid tumor patients. It signifies a profound advancement in precision medicine. The future landscape of solid tumor treatment may be profoundly shaped by these engineered cells. Tikva is actively preparing to lead this transformative charge.